tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2022 Oct 18;2131166.
doi: 10.1080/21645515.2022.2131166. Online ahead of print.
Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies
Cécile Janssen[SUP] 1 [/SUP], Anne Mosnier[SUP] 2 [/SUP], Gaëtan Gavazzi[SUP] 3 4 [/SUP], Behazine Combadière[SUP] 5 [/SUP], Pascal Crépey[SUP] 6 [/SUP], Jacques Gaillat[SUP] 1 [/SUP], Odile Launay[SUP] 7 [/SUP], Elisabeth Botelho-Nevers[SUP] 8 9 [/SUP]
Affiliations
Abstract
The lifting of non-pharmaceutical measures preventing transmission of SARS-CoV-2 (and other viruses, including influenza viruses) raises concerns about healthcare resources and fears of an increased number of cases of influenza and COVID-19. For the 2021-2022 influenza season, the WHO and >20 European countries promoted coadministration of influenza and COVID-19 vaccines. Recently, the French Health Authority recommended coupling the COVID-19 vaccination with the 2022-2023 influenza vaccination campaign for healthcare professionals and people at risk of severe COVID-19. The present systematic review examines published data on the safety, immunogenicity, efficacy/effectiveness, and acceptability/acceptance of coadministration of influenza and COVID-19 vaccines. No safety concerns or immune interferences were found whatever the vaccines or the age of vaccinated subjects (65- or 65+). No efficacy/effectiveness data were available. The results should reassure vaccinees and vaccinators in case of coadministration and increase vaccine coverage. Healthcare systems promoting coupled campaigns must provide the necessary means for successful coadministration.
Keywords: COVID-19 vaccines; Coadministration; influenza vaccines; patient acceptance of healthcare; patient compliance; patient safety; vaccine efficacy; vaccine immunogenicity.
. 2022 Oct 18;2131166.
doi: 10.1080/21645515.2022.2131166. Online ahead of print.
Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies
Cécile Janssen[SUP] 1 [/SUP], Anne Mosnier[SUP] 2 [/SUP], Gaëtan Gavazzi[SUP] 3 4 [/SUP], Behazine Combadière[SUP] 5 [/SUP], Pascal Crépey[SUP] 6 [/SUP], Jacques Gaillat[SUP] 1 [/SUP], Odile Launay[SUP] 7 [/SUP], Elisabeth Botelho-Nevers[SUP] 8 9 [/SUP]
Affiliations
- PMID: 36256633
- DOI: 10.1080/21645515.2022.2131166
Abstract
The lifting of non-pharmaceutical measures preventing transmission of SARS-CoV-2 (and other viruses, including influenza viruses) raises concerns about healthcare resources and fears of an increased number of cases of influenza and COVID-19. For the 2021-2022 influenza season, the WHO and >20 European countries promoted coadministration of influenza and COVID-19 vaccines. Recently, the French Health Authority recommended coupling the COVID-19 vaccination with the 2022-2023 influenza vaccination campaign for healthcare professionals and people at risk of severe COVID-19. The present systematic review examines published data on the safety, immunogenicity, efficacy/effectiveness, and acceptability/acceptance of coadministration of influenza and COVID-19 vaccines. No safety concerns or immune interferences were found whatever the vaccines or the age of vaccinated subjects (65- or 65+). No efficacy/effectiveness data were available. The results should reassure vaccinees and vaccinators in case of coadministration and increase vaccine coverage. Healthcare systems promoting coupled campaigns must provide the necessary means for successful coadministration.
Keywords: COVID-19 vaccines; Coadministration; influenza vaccines; patient acceptance of healthcare; patient compliance; patient safety; vaccine efficacy; vaccine immunogenicity.